Excision Repair Cross-Complementation Group 1 (ERCC1) participates in the repair of DNA intrastrand adducts and interstrand crosslinks, but its role as a predictive biomarker has never been fully validated. It has now been revealed that p53 mutation status should be considered concomitantly with ERCC1 to predict cisplatin efficacy.
http://bit.ly/2RESmKl
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.